Is Canopy Growth Corp (TSX:WEED) Still a Buy After its Massive Rally?

The past few weeks have seen a massive rally Canopy Growth Corp (TSX:WEED)(NYSE:CGC) stocks. Are they still a buy?

| More on:

It’s been a wild few weeks for Canopy Growth Corp. (TSX:WEED)(NYSE:CGC). In less than 10 days, the stock rallied from $32.15 to $52.10–a 62% gain. For most stocks, that would be an incredible annual return. For just a few days, it is absolutely phenomenal; a rally that harkens back to the heady days of 2017’s “crypto mania.”

Now, the logical question is this: “Is Canopy still a buy”?

To answer that question, we need to look at the factors driving the rally and what they mean for the company.

The $5 billion investment

The most obvious factor influencing the recent rally was the announcement that Constellation Brands Inc. (NYSE:STZ) would invest $5 billion in Canopy. Constellation purchased its shares as part of a deal with Canopy (rather than on the stock market), which means that the sale will inject approximately $4.5 billion in cash into the company.

This has a number of ramifications for Canopy, almost all of them positive. The company now has more funds to invest in infrastructure and overseas operations. New facilities in foreign countries could give Canopy more direct access to overseas markets. R&D investments–such as new cultivation techniques and technologies–could increase yields and lower the cost of revenue. New product lines could be developed, with beverages and sleep aids being two possibilities cited by Canopy’s CEO Bruce Linton.

It remains to be seen what Canopy will do will the proceeds from the deal, but the possibilities are endless. We have solid hints that international expansion and new product lines are among them.

Impending legalization

As most Canadians know, cannabis will be fully legalized on a federal level on October 17. This gives Canopy a clear path to increased revenue. Deloitte & Touche estimates that the recreational marijuana market in Canada is worth $8.7 billion annually. By contrast, the medical marijuana market is worth $5.7 billion a year. This makes the recreational market significantly larger than the medical market Canopy currently serves. In other words, in the domestic part of its operations, Canopy will soon have a much larger potential customer base to tap into. This could mean significant revenue growth if the company plays its cards right.

Red-hot revenue growth

Canopy is already seeing significant revenue growth in its core operations. In its most recent income statement, the company announced that it had grown revenue 63% from the same quarter last year, which is very strong growth. However, it should be noted that the company’s net loss increased in the same quarter, as a result of mounting costs.

Clearly, the cost of generating revenue is a major sticking point for Canopy. The question investors need to ask themselves is whether Canopy’s partnership with Constellation brands and opportunities in the recreational market, will bring the company to profitability. Personally I’d wait on future earnings announcements–after legalization has taken effect–before investing in Canopy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Investing

think thought consider
Stock Market

Billionaires Are Selling Apple Stock and Picking up This TSX Stock Instead

Billionaires like Warren Buffett continue to trim stakes in Apple stock, with others picking up this long-term stock instead.

Read more »

ways to boost income
Dividend Stocks

1 Excellent TSX Dividend Stock, Down 25%, to Buy and Hold for the Long Term

Down 25% from all-time highs, Tourmaline Oil is a TSX dividend stock that offers you a tasty yield of 5%…

Read more »

canadian energy oil
Energy Stocks

Is Baytex Energy Stock a Good Buy?

Baytex just hit a 12-month low. Is the stock now oversold?

Read more »

Start line on the highway
Dividend Stocks

1 Incredibly Cheap Canadian Dividend-Growth Stock to Buy Now and Hold for Decades

CN Rail (TSX:CNR) stock is incredibly cheap, but should investors join insiders by buying the dip?

Read more »

bulb idea thinking
Dividend Stocks

Down 13%, This Magnificent Dividend Stock Is a Screaming Buy

Sometimes, a moderately discounted, safe dividend stock is better than heavily discounted stock, offering an unsustainably high yield.

Read more »

a man relaxes with his feet on a pile of books
Investing

Outlook for Sun Life Financial Stock in 2025

Sun Life is up 25% this year. Are more gains on the way?

Read more »

Canadian Dollars bills
Dividend Stocks

Invest $15,000 in This Dividend Stock, Create $5,710.08 in Passive Income

This dividend stock is the perfect option if you're an investor looking for growth, as well as passive income through…

Read more »

woman looks out at horizon
Stocks for Beginners

Here’s How Much Canadians at 35 Need to Retire

If you want to create enough cash on hand to retire, then consider an ETF in one of the safest…

Read more »